Marina Collins
Family · Salisbury, MDNPI 1164176194
Payments from drug & device makers
Across 130 payments — averaging $26.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$558
- Viiv Healthcare Company$343
- Sanofi-aventis U.S. LLC$285
- Novo Nordisk$265
- AstraZeneca$224
- Boehringer Ingelheim$219
- plus $2K from 24 others
What the payments were for
- Food & beverage$3,411100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 27 | $558 |
| Viiv Healthcare Company | 9 | $343 |
| Sanofi-aventis U.S. LLC | 4 | $285 |
| Novo Nordisk | 10 | $265 |
| AstraZeneca | 7 | $224 |
| Boehringer Ingelheim | 9 | $219 |
| Exact Sciences | 10 | $215 |
| AbbVie | 9 | $215 |
| Pfizer | 7 | $126 |
| Sanofi | 1 | $125 |
| GSK | 5 | $103 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $97 |
| Phathom Pharmaceuticals, Inc. | 4 | $92 |
| Amgen | 4 | $75 |
| Medtronic | 2 | $70 |
| Bayer | 3 | $53 |
| Corcept Therapeutics | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Merck | 2 | $39 |
| Johnson & Johnson | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| BD | 1 | $21 |
| Electromed, Inc. | 1 | $19 |
| Biogen | 1 | $16 |
| Gilead | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Pharming Healthcare, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Insightec,inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,411 in reported general payments places this provider in the 90th percentile of 2,843 family providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 45 | $60,410 |
| OzempicSemaglutide | 38 | $48,269 |
| JardianceEmpagliflozin | 36 | $47,689 |
| EliquisApixaban | 44 | $34,714 |
| RybelsusSemaglutide | 15 | $25,638 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $21,466 |
| XareltoRivaroxaban | 17 | $20,838 |
| LinzessLinaclotide | 14 | $13,130 |
| JanuviaSitagliptin Phosphate | 15 | $8,133 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,133 |
| FarxigaDapagliflozin Propanediol | 11 | $5,885 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $5,778 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 14 | $4,261 |
| Atorvastatin Calcium | 271 | $4,167 |
| Amlodipine Besylate | 256 | $3,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $265 | $73,90753 claims |
| Lilly USA, LLCTrulicity | $558 | $60,41045 claims |
| Boehringer IngelheimJardiance | $219 | $47,68936 claims |
| PfizerEliquis | $126 | $34,71444 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $103 | $27,59930 claims |
| Johnson & JohnsonXarelto | $23 | $20,83817 claims |
| AbbVieLinzess, Synthroid | $215 | $14,10034 claims |
| MerckJanuvia | $39 | $8,13315 claims |
| AstraZenecaFarxiga | $224 | $5,88511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,843 family providers in Maryland.
Other family in Salisbury
- Caroline MansySalisbury$106K
- Joy MaulikSalisbury$47K
- Sarah ProffitSalisbury$10K
- Donna GraySalisbury$10K
- Ariana ChaoLutherville$727K
- Erika HoffmanPotomac$226K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.